Erythrocyte-binding therapeutics
US10800838B2 · kind B2 · utility
9Cited by
133References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 21, 2017 |
| Grant date | Oct 13, 2020 |
| Priority date | — |
| Expiry date | Nov 21, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/74
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.